Hemoadsorption Treatment of Patients with Acute Infective Endocarditis during Surgery with Cardiopulmonary Bypass - A Case Series

Introduction Infective endocarditis is a serious disease condition. Depending on the causative microorganism and clinical symptoms, cardiac surgery and valve replacement may be needed, posing additional risks to patients who may simultaneously suffer from septic shock. The combination of surgery bacterial spreadout and artificial cardiopulmonary bypass (CPB) surfaces results in a release of key inflammatory mediators leading to an overshooting systemic hyperinflammatory state frequently associated with compromised hemodynamic and organ function. Hemoadsorption might represent a potential approach to control the hyperinflammatory systemic reaction associated with the procedure itself and subsequent clinical conditions by reducing a broad range of immuno-regulatory mediators. Methods We describe 39 cardiac surgery patients with proven acute infective endocarditis obtaining valve replacement during CPB surgery in combination with intraoperative CytoSorb hemoadsorption. In comparison, we evaluated a historical group of 28 patients with infective endocarditis undergoing CPB surgery without intraoperative hemoadsorption. Results CytoSorb treatment was associated with a mitigated postoperative response of key cytokines and clinical metabolic parameters. Moreover, patients showed hemodynamic stability during and after the operation while the need for vasopressors was less pronounced within hours after completion of the procedure, which possibly could be attributed to the additional CytoSorb treatment. Intraoperative hemoperfusion treatment was well tolerated and safe without the occurrence of any CytoSorb device-related adverse event. Conclusions Thus, this interventional approach may open up potentially promising therapeutic options for critically-ill patients with acute infective endocarditis during and after cardiac surgery, with cytokine reduction, improved hemodynamic stability and organ function as seen in our patients.

[1]  C. Falk,et al.  Effect of extracorporeal cytokine removal on vascular barrier function in a septic shock patient , 2017, Journal of Intensive Care.

[2]  J. Takala,et al.  What’s new in surgical treatment of infective endocarditis? , 2016, Intensive Care Medicine.

[3]  A. Weymann,et al.  Combination of ECMO and cytokine adsorption therapy for severe sepsis with cardiogenic shock and ARDS due to Panton–Valentine leukocidin—positive Staphylococcus aureus pneumonia and H1N1 , 2016, Journal of Artificial Organs.

[4]  S. Nseir,et al.  Hyperoxemia as a risk factor for ventilator-associated pneumonia , 2016, Critical Care.

[5]  A. Spittler,et al.  Effect of hemoadsorption during cardiopulmonary bypass surgery – a blinded, randomized, controlled pilot study using a novel adsorbent , 2016, Critical Care.

[6]  K. Träger,et al.  Treatment of Post-Cardiopulmonary Bypass SIRS by Hemoadsorption: A Case Series , 2016, The International journal of artificial organs.

[7]  J. Zamorano,et al.  2015 ESC Guidelines for the management of infective endocarditis. , 2016, Revista española de cardiología.

[8]  H. Steltzer,et al.  Septic Shock Secondary to β-hemolytic Streptococcus-induced Necrotizing Fasciitis treated with a Novel Cytokine Adsorption Therapy , 2014, The International journal of artificial organs.

[9]  A. bstract Systemic Inflammatory Response Syndrome in Heart Surgery : New possibilities for treatment through the use of a cytokine adsorber during ECC ? , 2014 .

[10]  E. Macedo,et al.  Timing of renal replacement therapy initiation by AKIN classification system , 2013, Critical Care.

[11]  C. Putensen,et al.  A multicenter randomized controlled study of an extracorporeal cytokine hemoadsorption device in septic patients , 2013, Critical Care.

[12]  Gilles Clermont,et al.  Acute removal of common sepsis mediators does not explain the effects of extracorporeal blood purification in experimental sepsis. , 2012, Kidney international.

[13]  Samer A M Nashef,et al.  EuroSCORE II. , 2012, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[14]  P. Audia,et al.  In-Vitro Myoglobin Clearance by a Novel Sorbent System , 2009, Artificial cells, blood substitutes, and immobilization biotechnology.

[15]  John A Kellum,et al.  Effects of hemoadsorption on cytokine removal and short-term survival in septic rats , 2008, Critical care medicine.

[16]  John A Kellum,et al.  Hemoadsorption removes tumor necrosis factor, interleukin-6, and interleukin-10, reduces nuclear factor-&kgr;B DNA binding, and improves short-term survival in lethal endotoxemia* , 2004, Critical care medicine.

[17]  A Haverich,et al.  Systemic inflammatory response syndrome after cardiac operations. , 1996, The Annals of thoracic surgery.